Trial Profile
A Randomized, Double-blind, Active-controlled, Multicenter Phase 3 Trial to Evaluate the Safety and Efficacy of YH22162 in Subjects With Essential Hypertension Inappropriately Controlled on Telmisartan/Amlodipine Treatment
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 15 Sep 2022
Price :
$35
*
At a glance
- Drugs Amlodipine/chlortalidone/telmisartan (Primary) ; Amlodipine/telmisartan
- Indications Essential hypertension
- Focus Registrational; Therapeutic Use
- Sponsors Yuhan
- 12 Sep 2022 Results (n=176) assessing the efficacy and safety of low-dose triple combinations of amlodipine, telmisartan, and chlorthalidone in patients with essential hypertension, published in the Journal of Clinical Hypertension (Greenwich).
- 14 Feb 2017 Status changed from active, no longer recruiting to completed.
- 06 Dec 2016 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2016.